Physician profile
Maria Prelipcean
NPI 1457326779
$9,971.66
in general payments reported to CMS, 2019-2025
37 companies · $2,076 in 2025
The $2,076 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $1,143 · 2021: $776 · 2022: $1,380 · 2023: $1,576 · 2024: $1,476 · 2025: $2,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,080 · Education: $47.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,080.18 |
| Education | $47.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,225.60 | 2021-2025 | |
| Novo Nordisk INC | $1,165.61 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,006.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $853.29 | 2019-2025 | Freestyle Libre |
| Dexcom, INC. | $800.92 | 2019-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $797.15 | 2019-2025 | Jardiance, Synjardy, Trijardy Xr |
| Medtronic, INC. | $594.41 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Astrazeneca Pharmaceuticals LP | $528.75 | 2019-2024 | Farxiga |
| Corcept Therapeutics | $413.98 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $376.60 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $274.69 | 2019-2025 | Evenity, Tepezza, Prolia |
| Tandem Diabetes Care, INC. | $241.28 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $240.11 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $232.17 | 2019-2025 | |
| Ibsa Pharma INC. | $194.91 | 2019-2025 | Licart, Tirosint, Flector |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Prelipcean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.